[1]徐 林,赵东旭,侯忠衡,等.血清前白蛋白对TACE治疗不可切除肝细胞癌预后模型的建立与验证[J].介入放射学杂志,2024,33(07):767-773.
　XU Lin,ZHAO Dongxu,HOU Zhongheng,et al.Establishment and validation of a prognostic model based on preoperative serum prealbumin levels for patients with unresectable hepatocellular carcinoma receiving TACE treatment[J].journal interventional radiology,2024,33(07):767-773.
点击复制

血清前白蛋白对TACE治疗不可切除肝细胞癌预后模型的建立与验证()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
33
期数:
2024年07
页码:
767-773
栏目:
临床研究
出版日期:
2024-07-23

文章信息/Info

Title:
Establishment and validation of a prognostic model based on preoperative serum prealbumin levels for patients with unresectable hepatocellular carcinoma receiving TACE treatment
作者:
徐 林;  赵东旭;  侯忠衡;  倪才方
Author(s):
XU Lin;  ZHAO Dongxu;  HOU Zhongheng;  NI Caifang.
Department of Interventional Radiology， First Affiliated Hospital of Soochow University， Suzhou， Jiangsu Province 215006， China
关键词:
【关键词】 肝细胞癌;  前白蛋白;  诺模图;  预后;  总生存期
文献标志码:
A
摘要:
【摘要】 目的 建立术前血清前白蛋白水平的预后诺模图，预测TACE治疗不可切除肝细胞癌（HCC）患者总体生存期（OS）。方法 将2007年1月至2018年12月在苏州5家医疗中心接受TACE治疗的1 041例不可切除HCC患者分为训练队列（n=768）和验证队列（n=273）。Cox回归分析影响HCC患者1、2、3年（OS）的独立因素。基于独立危险因素构建诺模图，并在内部测试序列进行了验证。通过C指数、接收器工作特性曲线下面积（AUC）、校准曲线和判决曲线分析（DCA）来评估诺模图的性能。结果 Cox回归分析显示，AFP、BCLC、HBV感染、肝内血管侵犯、肿瘤数目、前白蛋白、PS、肿瘤大小均为影响TACE治疗不可切除HCC患者OS的独立危险因素。诺模图中训练队列C指数为0.739 （95%CI：0.719～0.759），验证队列C指数为0.715（95%CI：0.678～0.752）。训练队列中1、2和3年OS的AUC分别为0.877、0.794、0.799；验证队列的1、2和3年OS的AUC分别为0.840、0.741、0.671。诺模图AUC均高于其他评分系统，显示该诺模图具有良好区分度。校准曲线提示该模型的预测结果与实际观测值之间存在良好的一致性。DCA显示该诺模图具有很高的潜在临床实用性。诺模图风险评分显示，低风险组的患者存活率显著高于高风险组。结论 基于术前前白蛋白水平的诺模图对TACE治疗不可切除HCC患者显示出良好的预测能力。

参考文献/References:

［1］ Chang Y, Jeong SW，Young Jang J，et al. Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma［J］. Int J Mol Sci，2020，21:8165.
［2］ Pinero F，Dirchwolf M，Pessoa MG. Biomarkers in hepatocellular carcinoma: diagnosis， prognosis and treatment response assessment［J］. Cells， 2020， 9:1370.
［3］ Loftus TJ，Brown MP，Slish JH，et al. Serum Levels of Prealbumin and Albumin for Preoperative Risk Stratification［J］. Nutr Clin Pract， 2019， 34: 340- 348.
［4］ Huo RR， Liu HT， Deng ZJ， et al. Dose- response between serum prealbumin and all-cause mortality after hepatectomy in patients with hepatocellular carcinoma［J］. Front Oncol， 2020，10: 596691.
［5］ Ranasinghe RN，Biswas M，Vincent RP. Prealbumin: The clinical utility and analytical methodologies［J］. Ann Clin Biochem, 2022,59:7-14.
［6］ Zhu G， Tang Z， Huang R et al. CD36(+) cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factor［J］. Cell Discov， 2023， 9: 25.
［7］ Smith SH. Using albumin and prealbumin to assess nutritional status［J］. Nursing, 2017, 47:65-66.
［8］ Watanabe T， Shibata M， Nishiyama H， et al. Serum levels of rapid turnover proteins are decreased and related to systemic inflammation in patients with ovarian cancer［J］. Oncol Lett，2014， 7: 373- 377.
［9］ Arends J. Struggling with nutrition in patients with advanced cancer: nutrition and nourishment-focusing on metabolism and supportive care［J］. Ann Oncol, 2018, 29:ii27-ii34.
［10］ Li J，Du M，Li H，et al. Low Prealbumin Levels Were Associated with Increased Frequency of Hepatic Encephalopathy in Hepatitis B Virus(HBV)- Related Decompensated Cirrhosis［J］. Med Sci Monit， 2023， 29: e937772.
［11］ 侯忠衡， 张磊，王 祁，等. 术前血清前白蛋白对TACE治疗不可切除肝细胞癌患者预后的预测价值［J］. 介入放射学杂志， 2022， 31: 587- 592.
［12］ Chen S， Shen B，Wu Y， et al. The relationship between the efficacy of thermal ablation and inflammatory response and immune status in early hepatocellular carcinoma and the progress of postoperative adjuvant therapy［J］. Int Immunopharmacol， 2023， 119: 110228.
［13］ Prieto J， Melero I， Sangro B. Immunological landscape and immunotherapy of hepatocellular carcinoma［J］. Nat Rev Gastroen-terol Hepatol, 2015, 12:681-700.
［14］ Myron Johnson A，Merlini G，Sheldon J，et al. Clinical indications for plasma protein assays: transthyretin(prealbumin) in inflam-mation and malnutrition［J］. Clin Chem Lab Med， 2007， 45: 419- 426.
［15］ Yang L，Li A，Wang Y， et al. Intratumoral microbiota: roles in cancer initiation， development and therapeutic efficacy［J］. Signal Transduct Target Ther, 2023, 8:35.
［16］ Ferrero A，Vassallo D，Geuna M，et al. Immunonutrition in ovarian cancer: clinical and immunological impact?［J］. J Gynecol Oncol， 2022， 33: e77.
［17］ Luo Y，Xue Y，Mao L，et al. Prealbumin as a Predictor of Prognosis in Patients With Coronavirus Disease 2019［J］. Front Med (Lausanne)， 2020， 7: 374.
［18］ Wang WK，Tu CY，Shao CX，et al. Impact of enhanced recovery after surgery on postoperative rehabilitation，inflammation，and immunity in gastric carcinoma patients: a randomized clinical trial［J］. Braz J Med Biol Res， 2019， 52: e8265.
［19］ Goyal P，Salem R，Mouli SK. Role of interventional oncology in hepatocellular carcinoma: Future best practice beyond current guidelines［J］. Br J Radiol， 2022， 95: 20220379.
［20］ Han K，Kim JH. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system［J］. World J Gastroenterol, 2015, 21:10327- 10335.
［21］ Sidali S，Trepo E，Sutter O，et al. New concepts in the treatment of hepatocellular carcinoma［J］. United European Gastroenterol J,2022,10:765-774.
［22］ Jihye C，Jinsil S. Application of radiotherapeutic strategies in the BCLC- Defined stages of hepatocellular carcinoma［J］. Liver Cancer, 2012, 1:216- 225.
［23］ Yang JD， Kim WR， Park KW， et al. Model to estimate survival in ambulatory patients with hepatocellular carcinoma［J］. Hepatology， 2012， 56: 614- 621.
［24］ Rocha BMM，Dolan RD，Paiva CE，et al. Inflammation and performance status: the cornerstones of prognosis in advanced cancer［J］. J Pain Symptom Manage， 2023， 65: 348- 357.
［25］ Dolan RD，Daly L，Sim WMJ，Fallon M，et al. Comparison of the prognostic value of ECOG- PS，mGPS and BMI/WL: implications for a clinically important framework in the assessment and treatment of advanced cancer［J］. Clin Nutr， 2020， 39: 2889- 2895.
［26］ Reig M，Forner A，Rimola J，et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update［J］. J Hepatol， 2022， 76: 681- 693.
［27］ Tümen D，Heumann P，Gülow K，et al. Pathogenesis and current treatment strategies of hepatocellular carcinoma［J］. Biomedicines， 2022， 10: 3202.
［28］ Lee Q，Yu X，Yu W. The value of PIVKA- Ⅱ versus AFP for the diagnosis and detection of postoperative changes in hepatocellular carcinoma［J］. J Interv Med,2021,4:77- 81.
［29］ Zheng Y，Zhu M，Li M. Effects of alpha- fetoprotein on the occurrence and progression of hepatocellular carcinoma［J］. J Cancer Res Clin Oncol，2020，146: 2439- 2446.
［30］ 查俊豪，陆建，郭金和. 异常凝血酶原联合甲胎蛋白评价原发性肝癌TACE治疗价值［J］. 介入放射学杂志， 2019， 28: 591- 594.
［31］ de Visser KE，Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth［J］. Cancer Cell，2023， 41: 374- 403.

相似文献/References:

[1]姚雪松,李 槐.不可手术切除的肝细胞癌的疗效评价标准——改良ＲＥＣＩＳＴ标准更可靠[J].介入放射学杂志,2012,(03):177.
　. Ｔｈｅｒａｐｅｕｔｉｃ ｅｖａｌｕａｔｉｏｎ ｃｒｉｔｅｒｉｏｎ ｏｆ ｉｎｏｐｅｒａｂｌｅ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ： ｍｏｄｉｆｉｅｄ ＲＥＣＩＳＴ ａｓ ａ ｍｏｒｅ ｒｅｌｉａｂｌｅ ｓｔａｎｄａｒｄ[J].journal interventional radiology,2012,(07):177.
[2]梁茂全,苏洪英. 肝癌化疗栓塞前后甲胎蛋白变化模式的临床意义[J].介入放射学杂志,2012,(04):333.
　.Ｔｈｅ ｔｒａｎｓｆｏｒｍａｔｉｏｎ ｐａｔｔｅｒｎ ｏｆ ｓｅｒｕｍ аｆｅｔｏｐｒｏｔｅｉｎ ａｆｔｅｒ ｔｒａｎｓｃａｔｈｅｔｅｒ ａｒｔｅｒｉａｌ ｃｈｅｍｏｅｍｂｏｌｉｚａｔｉｏｎ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａ： ｉｔｓ ｃｌｉｎｉｃａｌ ｓｉｇｎｉｆｉｃａｎｃｅ [J].journal interventional radiology,2012,(07):333.
[3]孙 磊,施海彬,刘 圣,等.肝细胞癌肝动脉门静脉分流形成的相关因素分析[J].介入放射学杂志,2012,(03):206.
　,,et al.Ｔｈｅ ｆａｃｔｏｒｓ ｒｅｌａｔｅｄ ｔｏ ｔｈｅ ｆｏｒｍａｔｉｏｎ ｏｆ ａｒｔｅｒｉｏｐｏｒｔａｌ ｓｈｕｎｔｉｎｇ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ [J].journal interventional radiology,2012,(07):206.
[4]沈海洋,刘瑞宝,刘 岩,等. 肝右叶前、后段原发性肝癌TACE后VEGF及CD34的表达水平 ；[J].介入放射学杂志,2012,(06):469.
　SHEN Hai- yang,LIU Rui- bao,LIU Yan,et al. The expression levels of vascular endothelial growth factor and CD34 in residual cancerous tissues of primary hepatocellular carcinoma located at anterior and posterior segments of right lobe liver after TACE[J].journal interventional radiology,2012,(07):469.
[5]李晓峰,钱国军,张 磊,等. 微波高功率条件下消融原发性肝癌的初步研究[J].介入放射学杂志,2011,(12):974.
　LI Xiao-feng,QIAN Guo-jun,ZHANG Lei,et al.Microwave ablation with high output power for the treatment of hepatocellular carcinoma: a preliminary study[J].journal interventional radiology,2011,(07):974.
[6]彭辽河,胡晓燕,李 杰,等. 18F-FDG PET/CT显像在肝细胞癌TACE术后残留或复发病灶检出中的应用价值[J].介入放射学杂志,2012,(08):636.
　PENG Liao- he,HU Xiao- yan,LI Jie,et al. Clinical application of 18F- FDG PET/CT imaging in detecting residual lesions or recurrence foci of hepatocellular carcinoma after TACE treatment[J].journal interventional radiology,2012,(07):636.
[7]陆小华,朱小庆,茅国新.肝细胞癌相关单核苷酸多态性的研究进展[J].介入放射学杂志,2013,(06):520.
　LU Xiao? hua,ZHU Xiao? qing,MAO Guo? xin.. Hepatocellular carcinoma?蛳 related single nucleotide polymorphisms： recent advances in research[J].journal interventional radiology,2013,(07):520.
[8]姚雪松,闫 东,曾辉英,等.TACE联合索拉非尼治疗不能手术切除肝细胞癌介入治疗间隔时间的分析[J].介入放射学杂志,2014,(09):769.
　YAO Xue song,YAN Dong,ZENG Hui ying,et al.TACE combined with sorafenib for inoperable hepatocellular carcinoma： analysis of treatment interval[J].journal interventional radiology,2014,(07):769.
[9]姚雪松,闫 东,曾辉英,等. TACE联合索拉非尼治疗不能手术切除肝细胞肝癌50例[J].介入放射学杂志,2013,(05):381.
　YAO Xue? song,YAN Dong,ZENG Hui? ying,et al. Ttransarterial chemoembolization combined with sorafenib for inoperable hepatocellular carcinoma： a clinical analysis of 50 cases[J].journal interventional radiology,2013,(07):381.
[10]赵 松,陈学春,龙清云,等. 经肝动脉化疗栓塞联合射频消融治疗肝细胞癌疗效荟萃分析[J].介入放射学杂志,2013,(11):908.
　ZHAO Song,CHEN Xue? chun,LONG Qing? yun,et al. Transcatheter arterial chemoembolization combined with radiofrequency ablation for the treatment of hepatocellular carcinoma： a systematic review and Meta analysis[J].journal interventional radiology,2013,(07):908.
[11]侯忠衡,张 磊,王 祁,等.术前血清前白蛋白对TACE治疗不可切除肝细胞癌患者预后的预测价值 [J].介入放射学杂志,2022,31(06):587.
　HOU Zhongheng,ZHANG Lei,WANG Qi,et al.The clinical value of preoperative serum prealbumin level in predicting the prognosis of patients with inoperable HCC after receiving TACE： a multicenter retrospective study[J].journal interventional radiology,2022,31(07):587.

备注/Memo

备注/Memo:
（收稿日期：2023-08-14）
（本文编辑：新 宇）
更新日期/Last Update: 2024-07-23